Naftopidil and tolterodine in the medical expulsive therapy for intramural ureteral stones: a prospective randomized study.
- Published in:
- Urological Research, 2012, v. 40, n. 6, p. 757, doi. 10.1007/s00240-012-0498-7
- By:
- Publication type:
- Article
Works matching DE "TOLTERODINE"
Results: 131
1
2
Efficacy of tolterodine for medical treatment of intramural ureteral stone with vesical irritability.
- Published in:
- Urological Research, 2011, v. 39, n. 3, p. 213, doi. 10.1007/s00240-010-0337-7
- By:
- Publication type:
- Article
3
Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.
- Published in:
- European Journal of Clinical Pharmacology, 2018, v. 74, n. 2, p. 193, doi. 10.1007/s00228-017-2359-3
- By:
- Publication type:
- Article
4
Comparative adherence to oxybutynin or tolterodine among older patients.
- Published in:
- 2012
- By:
- Publication type:
- Letter
5
Comparative adherence to oxybutynin or tolterodine among older patients.
- Published in:
- 2012
- By:
- Publication type:
- Letter
6
Comparative adherence to oxybutynin or tolterodine among older patients.
- Published in:
- European Journal of Clinical Pharmacology, 2012, v. 68, n. 1, p. 97, doi. 10.1007/s00228-011-1090-8
- By:
- Publication type:
- Article
7
Managing urinary incontinence in patients living with dementia.
- Published in:
- British Journal of Community Nursing, 2018, v. 23, n. 1, p. 24, doi. 10.12968/bjcn.2018.23.1.24
- By:
- Publication type:
- Article
8
Benign Prostat Hiperplazisinde Tolterodin ve Tamsulosin Kombinasyonunun Semptomlar ve Mesane Çlkam Obstrüksiyonu Üzerine Etkisi.
- Published in:
- Journal of Turgut Ozal Medical Center, 2013, v. 20, n. 1, p. 12, doi. 10.7247/jtomc.20.1.4
- By:
- Publication type:
- Article
9
Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
- Published in:
- Scandinavian Journal of Urology (Taylor & Francis Ltd), 2014, v. 48, n. 1, p. 79, doi. 10.3109/21681805.2013.814707
- By:
- Publication type:
- Article
10
Tamsulosin and tolterodine in the medical expulsive therapy for intramural ureteral stones with vesical irritability: a prospective randomized study.
- Published in:
- Urolithiasis, 2013, v. 41, n. 5, p. 417, doi. 10.1007/s00240-013-0599-y
- By:
- Publication type:
- Article
11
Clinical Use of Tolterodine Extended Release in Overactive Bladder.
- Published in:
- Clinical Medicine Insights: Urology, 2012, n. 6, p. 1, doi. 10.4137/CMU.S6425
- By:
- Publication type:
- Article
12
Development of an Ion Chromatography Method for Analysis of Organic Anions (Fumarate, Oxalate, Succinate, and Tartrate) in Single Chromatographic Conditions.
- Published in:
- Scientia Pharmaceutica, 2015, v. 83, n. 4, p. 611, doi. 10.3797/scipharm.1503-15
- By:
- Publication type:
- Article
13
Isolation, Identification, and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in the Tolterodine Tartrate Formulation.
- Published in:
- Scientia Pharmaceutica, 2015, v. 83, n. 1, p. 65, doi. 10.3797/scipharm.1407-18
- By:
- Publication type:
- Article
14
A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples.
- Published in:
- Scientia Pharmaceutica, 2012, v. 80, n. 1, p. 101, doi. 10.3797/scipharm.1110-14
- By:
- Publication type:
- Article
15
Comparison of efficacy and side-effects of Oxybutynin and Tolterodine in the treatment of overactive bladder.
- Published in:
- Tehran University Medical Journal, 2011, v. 69, n. 5, p. 302
- By:
- Publication type:
- Article
16
Combination of Sacral Neuromodulation and Tolterodine for Treatment of Idiopathic Overactive Bladder in Women: A Clinical Trial.
- Published in:
- Urology Journal, 2014, v. 11, n. 4, p. 1800
- By:
- Publication type:
- Article
17
CNE SERIES. Demystifying Nocturia: Identifying the Cause and Tailoring the Treatment.
- Published in:
- Urologic Nursing, 2010, v. 30, n. 5, p. 276, doi. 10.7257/1053-816X.2010.30.5.276
- By:
- Publication type:
- Article
18
FDA approval signals more 'homework' on the horizon in trials.
- Published in:
- Nature Medicine, 2011, v. 17, n. 7, p. 754, doi. 10.1038/nm0711-754b
- By:
- Publication type:
- Article
19
2012 - Review: Drugs for urgency urinary incontinence improve continence in women.
- Published in:
- ACP Journal Club, 2012, v. 157, n. 8, p. 1, doi. 10.7326/0003-4819-157-8-201210160-02004
- By:
- Publication type:
- Article
20
Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
- Published in:
- Pharmacotherapy, 2018, v. 38, n. 6, p. 628, doi. 10.1002/phar.2121
- By:
- Publication type:
- Article
21
An overactive bladder treatment: Mirabegron versus Tolterodine.
- Published in:
- Journal of Emergency Medicine, Trauma & Acute Care, 2022, v. 2022, n. 1, p. 1, doi. 10.5339/jemtac.2022.qhc.33
- By:
- Publication type:
- Article
22
Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment—Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 1, p. 80, doi. 10.1002/cpdd.968
- By:
- Publication type:
- Article
23
Desmopressin Plus Tolterodine vs Desmopressin Plus Indomethacin for Refractory Pediatric Enuresis: An Open-label Randomized Controlled Trial.
- Published in:
- Indian Pediatrics, 2023, v. 60, n. 6, p. 447, doi. 10.1007/s13312-023-2906-1
- By:
- Publication type:
- Article
24
坦洛新联合托特罗定对老年膀胱过度活动综合症患者P2X3受体表达的影响.
- Published in:
- Progress in Modern Biomedicine, 2017, v. 17, n. 17, p. 3347, doi. 10.13241/j.cnki.pmb.2017.17.037
- By:
- Publication type:
- Article
25
Sensitive and selective determination of tolterodine tartrate and its electrochemical investigation on solid carbon based electrodes.
- Published in:
- Journal of Analytical Chemistry, 2014, v. 69, n. 10, p. 970, doi. 10.1134/S1061934814100049
- By:
- Publication type:
- Article
26
Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms ( LUTS) and overactive bladder: a randomized controlled trial.
- Published in:
- BJU International, 2016, v. 117, n. 2, p. 307, doi. 10.1111/bju.13267
- By:
- Publication type:
- Article
27
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
- Published in:
- BJU International, 2013, v. 112, n. 3, p. 373, doi. 10.1111/bju.12174
- By:
- Publication type:
- Article
28
Antidiuretic effect of antimuscarinic agents in rat model depends on C-fibre afferent nerves in the bladder.
- Published in:
- BJU International, 2013, v. 112, n. 1, p. 131, doi. 10.1111/j.1464-410X.2012.11747.x
- By:
- Publication type:
- Article
29
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
- Published in:
- BJU International, 2012, v. 110, n. 11, p. 1767, doi. 10.1111/j.1464-410X.2012.11023.x
- By:
- Publication type:
- Article
30
Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β<sub>3</sub>-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
- Published in:
- BJU International, 2012, v. 110, n. 2b, p. E132, doi. 10.1111/j.1464-410X.2012.11240.x
- By:
- Publication type:
- Article
31
MODULATION OF NON-VOIDING ACTIVITY BY THE MUSCARINERGIC ANTAGONIST TOLTERODINE AND THE β<sub>3</sub>-ADRENOCEPTOR AGONIST MIRABEGRON IN CONSCIOUS RATS WITH PARTIAL OUTFLOW OBSTRUCTION.
- Published in:
- BJU International, 2012, v. 110, n. 2b, p. E143, doi. 10.1111/j.1464-410X.2012.11259.x
- By:
- Publication type:
- Article
32
Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.
- Published in:
- BJU International, 2012, v. 110, n. 2b, p. E125, doi. 10.1111/j.1464-410X.2011.10838.x
- By:
- Publication type:
- Article
33
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
- Published in:
- BJU International, 2011, v. 107, n. 9, p. 1432, doi. 10.1111/j.1464-410X.2010.09640.x
- By:
- Publication type:
- Article
34
Early onset of fesoterodine efficacy in subjects with overactive bladder.
- Published in:
- BJU International, 2011, v. 107, n. 4, p. 598, doi. 10.1111/j.1464-410X.2010.09586.x
- By:
- Publication type:
- Article
35
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
- Published in:
- BJU International, 2010, v. 106, n. 9, p. 1332, doi. 10.1111/j.1464-410X.2010.09359.x
- By:
- Publication type:
- Article
36
Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000 to 2013.
- Published in:
- Clinical Pediatrics, 2017, v. 56, n. 1, p. 55, doi. 10.1177/0009922816641366
- By:
- Publication type:
- Article
37
Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder.
- Published in:
- Journal of Microencapsulation, 2013, v. 30, n. 2, p. 116, doi. 10.3109/02652048.2012.704950
- By:
- Publication type:
- Article
38
Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions.
- Published in:
- American Journal of Pharmacy Benefits, 2018, v. 10, n. 1, p. 11
- By:
- Publication type:
- Article
39
Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study.
- Published in:
- Canadian Urological Association Journal, 2018, v. 12, n. 3, p. E142, doi. 10.5489/cuaj.4541
- By:
- Publication type:
- Article
40
Double anticholinergic therapy for refractory neurogenic and nonneurogenic detrusor overactivity in children: Long-term results of a prospective open-label study.
- Published in:
- Canadian Urological Association Journal, 2014, v. 8, n. 5/6, p. 175, doi. 10.5489/cuaj.1362
- By:
- Publication type:
- Article
41
Moderated Poster Session IV: Basic Science & Education Friday, November 1,2013 10:45 AM -12:30 PM.
- Published in:
- 2013
- Publication type:
- Abstract
42
A Review of Anticholinergic Medications for Overactive Bladder Symptoms.
- Published in:
- MEDSURG Nursing, 2013, v. 22, n. 2, p. 119
- By:
- Publication type:
- Article
43
The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
44
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects.
- Published in:
- World Journal of Urology, 2010, v. 28, n. 5, p. 651, doi. 10.1007/s00345-010-0513-y
- By:
- Publication type:
- Article
45
The Antimuscarinic Agent Tolterodine Regulates Bladder Extracellular Matrix in Partial Bladder Outlet Obstruction in Rats.
- Published in:
- Cellular Physiology & Biochemistry (Karger AG), 2018, v. 46, n. 1, p. 36, doi. 10.1159/000488407
- By:
- Publication type:
- Article
46
Tolterodine to Relieve Urinary Symptoms Following Transurethral Resection of the Prostate: A Double-Blind Placebo-Controlled Randomized Clinical Trial.
- Published in:
- Korean Journal of Urology, 2014, v. 55, n. 4, p. 260, doi. 10.4111/kju.2014.55.4.260
- By:
- Publication type:
- Article
47
Patient-Focused Treatment Decisions in the Management of Overactive Bladder.
- Published in:
- Journal of Managed Care Medicine, 2022, v. 25, n. 3, p. 37
- By:
- Publication type:
- Article
48
Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers.
- Published in:
- Drug Discoveries & Therapeutics, 2010, v. 4, n. 1, p. 44
- By:
- Publication type:
- Article
49
Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in western and east Asian populations.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 8, p. 928, doi. 10.1002/jcph.274
- By:
- Publication type:
- Article
50
Effects of Hepatic Dysfunction on the Single-Dose Pharmacokinetics of Fesoterodine.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 3, p. 397, doi. 10.1177/0091270010365547
- By:
- Publication type:
- Article